Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

 Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

Baysient to Release iDose Software Technology Platform 1.0 to Reduce the Biosimilar Cost in Market

  • The 12-month clinical validation study (NCT02453776) data demonstrated the reduction “switching” from lower cost infliximab to more expensive biologics by 66%. Also, similar studies are ongoing in 9 countries on 3 continents
  • The results were already presented at ECCO, Copenhagen, Mar 2019 and DDW, San Diego, May 2019 and the Baysient pipeline includes CDS for 25 FDA approved anti-inflammatory biologics. The HCPs using iDose software’s CDS reduced the cost $726,000 per 100 patients
  • The iDose algorithm is a cloud base SaaS and is HIPAA-compliant, compatible with EMRs offered in the US and Canada, combines the PK data with Bayesian learning (non-AI machine learning) and forecasting, also enables the physicians to understand how to keep the amount of drug in patient’s body from falling below the physician-selected target

Click here to read full press release/ article | Ref: PR Newswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post